» Articles » PMID: 38522065

Enhancing RECK Expression Through MiR-21 Inhibition: A Promising Strategy for Bladder Carcinoma Control

Abstract

Bladder carcinoma (BC) is the tenth most frequent malignancy worldwide, with high morbidity and mortality rates. Despite recent treatment advances, high-grade BC and muscle-invasive BC present with significant progression and recurrence rates, urging the need for alternative treatments. The microRNA-21 (miR-21) has superexpression in many malignancies and is associated with cellular invasion and progression. One of its mechanisms of action is the regulation of RECK, a tumor suppressor gene responsible for inhibiting metalloproteinases, including MMP9. In a high-grade urothelial cancer cell line, we aimed to assess if miR-21 downregulation would promote RECK expression and decrease MMP9 expression. We also evaluated cellular migration and proliferation potential by inhibition of this pathway. In a T24 cell line, we inhibited miR-21 expression by transfection of a specific microRNA inhibitor (anti-miR-21). There were also control and scramble groups, the last with a negative microRNA transfected. After the procedure, we performed a genetic expression analysis of miR-21, RECK, and MMP9 through qPCR. Migration, proliferation, and protein expression were evaluated via wound healing assay, colony formation assay, flow cytometry, and immunofluorescence.After anti-miR-21 transfection, miR-21 expression decreased with RECK upregulation and MMP9 downregulation. The immunofluorescence assay showed a significant increase in RECK protein expression (p < 0.0001) and a decrease in MMP9 protein expression (p = 0.0101). The anti-miR-21 transfection significantly reduced cellular migration in the wound healing assay (p < 0.0001). Furthermore, in the colony formation assay, the anti-miR-21 group demonstrated reduced cellular proliferation (p = 0.0008), also revealed in the cell cycle analysis by flow cytometry (p = 0.0038). Our results corroborate the hypothesis that miR-21 is associated with BC cellular migration and proliferation, revealing its potential as a new effective treatment for this pathology.

Citing Articles

Research Progress on Natural Products That Regulate miRNAs in the Treatment of Osteosarcoma.

Wang L, Liu X, Lv H, Zhang H, Lin R, Xu S Biology (Basel). 2025; 14(1).

PMID: 39857292 PMC: 11759184. DOI: 10.3390/biology14010061.


MicroRNA-21 in urologic cancers: from molecular mechanisms to clinical implications.

Gan L, Zheng L, Zou J, Luo P, Chen T, Zou J Front Cell Dev Biol. 2024; 12:1437951.

PMID: 39114567 PMC: 11304453. DOI: 10.3389/fcell.2024.1437951.

References
1.
Alexius-Lindgren M, Andersson E, Lindstedt I, Engstrom W . The RECK gene and biological malignancy--its significance in angiogenesis and inhibition of matrix metalloproteinases. Anticancer Res. 2014; 34(8):3867-73. View

2.
Asangani I, Rasheed S, Nikolova D, Leupold J, Colburn N, Post S . MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2007; 27(15):2128-36. DOI: 10.1038/sj.onc.1210856. View

3.
Bajorin D, Witjes J, Gschwend J, Schenker M, Valderrama B, Tomita Y . Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021; 384(22):2102-2114. PMC: 8215888. DOI: 10.1056/NEJMoa2034442. View

4.
Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

5.
Chen D, Guo Y, Chen Y, Guo Q, Chen J, Li Y . LncRNA growth arrest-specific transcript 5 targets miR-21 gene and regulates bladder cancer cell proliferation and apoptosis through PTEN. Cancer Med. 2020; 9(8):2846-2858. PMC: 7163107. DOI: 10.1002/cam4.2664. View